Voltage-gated L-type calcium channel · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Voltage-gated L-type calcium channel shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block. 15 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q13936. Start with cardiovascular disease, then reuse UniProt Q13936 as the stable protein anchor across project notes and exports.
Start with cardiovascular disease, then reuse UniProt Q13936 as the stable protein anchor across project notes and exports.
Voltage-gated L-type calcium channel shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block. 15 linked drugs remain visible in the same block.
Start review with cardiovascular disease because it currently carries approved-linked support. Linked drugs include BARNIDIPINE, BENIDIPINE, CILNIDIPINE, CLEVIDIPINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyVoltage-dependent L-type calcium channel subunit alpha-1C
Review this target as Voltage-gated L-type calcium channel, mapped to UniProt Q13936. ChEMBL maps the protein component as Voltage-dependent L-type calcium channel subunit alpha-1C. Sequence length is 2221 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Voltage-gated L-type calcium channel as ChEMBL target CHEMBL2095229, mapped to UniProt Q13936. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Voltage-gated L-type calcium channel is the right protein anchor across sources, using UniProt Q13936 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why cardiovascular disease is currently framed as approved-linked support. It currently carries 15 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Voltage-gated L-type calcium channel |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | Q13936 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Voltage-dependent L-type calcium channel subunit alpha-1C |
| UniProt Accession | Q13936 |
| Component Type | Protein |
| Sequence Length | 2221 aa |
Voltage-dependent L-type calcium channel subunit alpha-1C
Review this target as Voltage-gated L-type calcium channel, mapped to UniProt Q13936. ChEMBL maps the protein component as Voltage-dependent L-type calcium channel subunit alpha-1C. Sequence length is 2221 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Voltage-gated L-type calcium channel shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block.
Start review with cardiovascular disease because it currently carries approved-linked support. Linked drugs include BARNIDIPINE, BENIDIPINE, CILNIDIPINE, CLEVIDIPINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL286157 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL317044 | 10.89 | IC50 | 0.013 | Preclinical |
| CHEMBL441428 | 10.82 | IC50 | 0.015 | Preclinical |
| CHEMBL286598 | 10.77 | IC50 | 0.017 | Preclinical |
| CHEMBL37402 | 10.66 | IC50 | 0.022 | Preclinical |
| CHEMBL103806 | 10.57 | IC50 | 0.027 | Preclinical |
| CHEMBL37899 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL204616 | 10.48 | IC50 | 0.033 | Preclinical |
| CHEMBL35368 | 10.35 | IC50 | 0.045 | Preclinical |
| CHEMBL1099207 | 10.34 | IC50 | 0.046 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein format | 79 | 24 | 5.8 |
| assay format | 17 | 16 | 6.7 |
| cell-based format | 15 | 13 | 4.9 |
| cell membrane format | 4 | 7 | 7.2 |
| tissue-based format | 2 | 19 | 10.1 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 56 | 55 | 5.3 |
| assay format | 18 | 15 | 5.7 |
| tissue-based format | 5 | 26 | 7.7 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 4 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 0 | — |
| protein format | 1 | 0 | — |